AOD-9604 vs Frag 176-191 — same fragment, different framings

The base sequence is identical. Both refer to amino acids 176 through 191 of human growth hormone — the C-terminal 16-residue stretch that research has associated with the lipolytic activity of the full-length hormone. When researchers at Monash University synthesized this fragment in the early 1990s for pharmaceutical development, they added a tyrosine residue at the N-terminus of the sequence for practical reasons: tyrosine at position 1 aids in synthesis, provides a spectroscopic handle for measuring concentration, and may contribute to the fragment's stability. This gave the pharmaceutical candidate the chemical description Tyr-hGH(177-191), a 17-residue peptide that begins with the added tyrosine and runs through the natural C-terminal end of hGH.

Metabolic Pharmaceuticals, the Australian company that developed the compound clinically, used the proprietary designation AOD-9604 — anti-obesity drug candidate number 9604. That name traveled with the compound through its clinical trial program, its intellectual property filings, and the regulatory correspondence with the Therapeutic Goods Administration. AOD-9604 as a designation is inseparable from the pharmaceutical development context.

The research-peptide market, which operates separately from the pharmaceutical pipeline and sells compounds for laboratory and research purposes, developed its own naming conventions. In that context, the fragment of hGH spanning residues 176-191 circulates under the name Frag 176-191 or hGH Fragment 176-191. The naming reflects the source: the fragment of human growth hormone, identified by its position in the amino acid sequence. Some suppliers of Frag 176-191 include the N-terminal tyrosine and some do not — and this is the structural point where the two names diverge in principle, though not always in practice.

Frag 176-191 without the added tyrosine is a 16-residue peptide beginning with the native hGH sequence at position 176. AOD-9604 is technically a 17-residue peptide beginning with the synthetic tyrosine before position 177. In terms of the core functional domain — the amino acid stretch associated with beta-3 adrenergic receptor interaction and lipolysis stimulation — both constructs contain the same sequence. The added tyrosine in AOD-9604 is structural and synthetic scaffolding; it is not thought to be the functional driver of the lipolytic activity. When researchers discuss the mechanism, they're discussing the 176-191 segment regardless of whether they're calling the compound AOD-9604 or Frag 176-191.

In the research peptide market, "Frag 176-191" is almost universally used for the compound sold in vials, lyophilized, reconstituted with bacteriostatic water, and administered by subcutaneous injection. It's the standard research-peptide format: a measured amount of peptide supplied for laboratory study. "AOD-9604" more often appears in compounding pharmacy contexts — troches, capsules, and occasionally injectable preparations supplied through licensed compounding pharmacies under prescriber authorization. The distinction is partly commercial, partly regulatory, and only minimally chemical.

The regulatory boundary between these two framings is real and meaningful even when the molecule is essentially the same. A licensed compounding pharmacy in the United States operates under a different legal framework than a research peptide supplier. Compounding pharmacies prepare compounds under prescriber order, are subject to state pharmacy board oversight and, depending on their categorization, FDA oversight. They are not supposed to compound substances that are essentially copies of FDA-approved drugs, but they can compound drugs that are not FDA-approved if there is a clinical rationale and a valid prescriber-patient relationship. AOD-9604 compounded by a licensed pharmacy occupies this space: not FDA-approved, but prepared in a regulated context for a specific patient.

Research peptide suppliers, by contrast, typically sell their compounds with the disclaimer that they are "for research use only, not for human use." This is a legal formulation that creates a classification distinction — the compound is being sold as a laboratory reagent rather than a drug — though the practical use of these compounds is widely understood to extend beyond laboratory settings. The FDA's enforcement posture on research peptide suppliers has varied over time and has tightened in recent years, particularly for peptides with clinical trial histories that give them more clearly drug-like status. AOD-9604, with its Phase II trial record and prior regulatory engagement, occupies a different risk profile for suppliers than a purely preclinical compound.

The naming issue matters for a practical reason beyond taxonomy: it creates the illusion that two separate bodies of evidence exist for two separate compounds, when in fact they share the same research record. When someone asks whether Frag 176-191 has human trial data, the honest answer is: only if you count the AOD-9604 trials, which studied essentially the same molecule. The clinical evidence base is single and shared, even though the names suggest distinct compounds with distinct histories. Anyone evaluating the research literature on Frag 176-191 who doesn't search for AOD-9604 is missing almost all of the human data that exists. And anyone evaluating AOD-9604 who encounters "clinically proven" framing should understand that the clinical program used an oral formulation in obese patients — not the subcutaneous research-peptide preparation that most people now use.

Peptide nomenclature is, broadly, a mess. It developed in parallel across pharmaceutical, academic, and commercial contexts, with each domain applying its own conventions without reference to the others. The same compound can have a chemical name, an IUPAC designation, a developmental code name, a proprietary trade name from the pharmaceutical company, a research-peptide market name, and several informal community abbreviations — all referring to the same molecular structure. AOD-9604 and Frag 176-191 are a relatively mild example: the overlap is nearly total, the chemical difference is minimal, and the names at least point in an identifiable direction. Other peptide naming situations are far more tangled.

What this particular naming situation reveals about the regulatory landscape is instructive. The same molecular entity can be positioned as a pharmaceutical drug candidate, a compounded medication, and a research-use-only laboratory reagent, simultaneously, by different actors operating under different legal frameworks. Which framing applies in any given transaction depends on who is selling, to whom, for what stated purpose, through what channel, and in what jurisdiction — not on the chemistry of the compound itself. The molecule doesn't change. The regulatory category it occupies shifts entirely based on context.

Understanding this doesn't resolve the question of what to do with the information. It does make clear that when you encounter AOD-9604 from a compounding pharmacy and Frag 176-191 from a research supplier, the decision points are about regulatory context and provider relationship — not about accessing meaningfully different compounds with different evidence bases. The research record is shared. The safety data, modest as it is, applies to both. The efficacy questions that remain unanswered apply equally. The name on the label is context, not chemistry.